共 102 条
[1]
Oechslin EN(2000)Mode of death in adults with congenital heart disease Am J Cardiol 86 1111-6
[2]
Harrison DA(2013)The challenge of managing pulmonary arterial hypertension in adults with congenital heart disease Expert Rev Cardiovasc Ther 11 919-31
[3]
Connelly MS(2009)Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down’s syndrome Am J Cardiol 103 1309-15
[4]
Webb GD(2007)Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry Int J Cardiol 120 198-204
[5]
Siu SC(2013)Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease Int J Cardiol 164 64-9
[6]
Radke RM(2013)High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease Congenit Heart Dis 8 520-6
[7]
Diller G-P(2013)Latent pulmonary hypertension in atrial septal defect: Dynamic stress echocardiography reveals unapparent pulmonary hypertension and confirms rapid normalisation after ASD closure Neth Heart J 21 333-43
[8]
Baumgartner H(2008)Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial Lancet 371 2093-100
[9]
Duffels MGJ(2006)Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study Circulation 114 48-54
[10]
Vis JC(2010)Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan Ther Clin Risk Manag 6 359-66